Apellis Pharmaceuticals, Inc. Insider Trading

APLS

Last 12 months

Insiders sold $2.79M and bought nothing on the open market.

8% of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in May 2020.

Net open-market

−$2.79M

0 buys · 27 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

May 2020

May 8, 2020

Get an email when APLS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Feb 11	Mark Jeffrey Delong Chief Business & Strat Officer	SoldNo plan	368	$22.15	8K	0.3%	Form 4
Jan 22	Caroline Baumal Chief Medical Officer	SoldNo plan	2,797	$21.77	61K	3.1%	Form 4
Jan 22	James George Chopas VP/Chief Accounting Officer	SoldNo plan	2,064	$21.77	45K	4.0%	Form 4
Jan 22	Mark Jeffrey Delong Chief Business & Strat Officer	SoldNo plan	3,371	$21.77	73K	4.1%	Form 4
Jan 22	Pascal Deschatelets Chief Scientific Officer	SoldNo plan	5,928	$21.77	129K	0.5%	Form 4
Jan 22	Cedric Francois Chief Executive Officer	SoldNo plan	27,192	$21.77	592K	1.7%	Form 4
Jan 22	Nur Nicholson Chief Technical Officer	SoldNo plan	7,725	$21.77	168K	9.8%	Form 4
Jan 22	Timothy Eugene Sullivan Chief Financial Officer	SoldNo plan	10,287	$21.77	224K	6.3%	Form 4
Jan 22	David O. Watson General Counsel	SoldNo plan	7,832	$21.77	171K	5.0%	Form 4
Jan 20	Caroline Baumal Chief Medical Officer	SoldNo plan	1,882	$19.79	37K	2.1%	Form 4
Jan 20	James George Chopas VP/Chief Accounting Officer	SoldNo plan	726	$19.79	14K	1.4%	Form 4
Jan 20	Mark Jeffrey Delong Chief Business & Strat Officer	SoldNo plan	1,334	$19.79	26K	1.6%	Form 4
Jan 20	Pascal Deschatelets Chief Scientific Officer	SoldNo plan	909	$19.79	18K	<0.1%	Form 4
Jan 20	Cedric Francois Chief Executive Officer	SoldNo plan	8,182	$19.79	162K	0.5%	Form 4
Jan 20	Nur Nicholson Chief Technical Officer	SoldNo plan	2,203	$19.79	44K	2.7%	Form 4
Jan 20	Timothy Eugene Sullivan Chief Financial Officer	SoldNo plan	2,892	$19.79	57K	1.7%	Form 4
Jan 20	David O. Watson General Counsel	SoldNo plan	2,475	$19.79	49K	1.6%	Form 4
Jan 13	James George Chopas VP/Chief Accounting Officer	SoldNo plan	873	$22.19	19K	1.6%	Form 4
Jan 13	Mark Jeffrey Delong Chief Business & Strat Officer	SoldNo plan	1,780	$22.19	39K	2.1%	Form 4
Jan 13	Pascal Deschatelets Chief Scientific Officer	SoldNo plan	2,277	$22.19	51K	0.2%	Form 4
Jan 13	Cedric Francois Chief Executive Officer	SoldNo plan	10,186	$22.19	226K	0.6%	Form 4
Jan 13	Nur Nicholson Chief Technical Officer	SoldNo plan	2,618	$22.19	58K	3.1%	Form 4
Jan 13	Timothy Eugene Sullivan Chief Financial Officer	SoldNo plan	3,856	$22.19	86K	2.3%	Form 4
Jan 13	David O. Watson General Counsel	SoldNo plan	5,780	$22.19	128K	3.5%	Form 4
Jan 5	Caroline Baumal Chief Medical Officer	SoldNo plan	3,020	$25.53	77K	3.2%	Form 4
Dec 16, 2025	David O. Watson General Counsel	Sold10b5-1 plan	5,000	$24.49	122K	3.0%	Form 4
Nov 17, 2025	David O. Watson General Counsel	Sold10b5-1 plan	5,000	$20.06	100K	2.9%	Form 4
Oct 21, 2025	Timothy Eugene Sullivan Chief Financial Officer	Sold10b5-1 plan	10,000	$28.03	280K	5.5%	Form 4
Oct 16, 2025	David O. Watson General Counsel	Sold10b5-1 plan	5,000	$25.22	126K	2.8%	Form 4
Oct 10, 2025	A. Sinclair Dunlop Director	Sold10b5-1 plan	31,092	$23.72	738K	16%	Form 4
Sep 30, 2025	A. Sinclair Dunlop Director	Sold10b5-1 plan	31,092	$22.58	702K	14%	Form 4
Sep 19, 2025	A. Sinclair Dunlop Director	Sold10b5-1 plan	31,092	$22.95	714K	12%	Form 4
Sep 16, 2025	David O. Watson General Counsel	Sold10b5-1 plan	5,000	$24.34	122K	2.7%	Form 4
Sep 15, 2025	James George Chopas VP/Chief Accounting Officer	SoldNo plan	189	$24.19	5K	0.4%	Form 4
Sep 10, 2025	David O. Watson General Counsel	SoldNo plan	20,000	$26.17	523K	9.8%	Form 4
Sep 8, 2025	Timothy Eugene Sullivan Chief Financial Officer	Sold10b5-1 plan 2 parts	42,729	$27.85 average	$1.19M	20%	Form 4
Sep 2, 2025	James George Chopas VP/Chief Accounting Officer	SoldNo plan	548	$28.08	15K	1.0%	Form 4
Aug 27, 2025 – Aug 28, 2025	Cedric Francois Chief Executive Officer	SoldNo plan 2 parts	225,000	$28.23 average	$6.35M	12%	Form 4
Aug 18, 2025	David O. Watson General Counsel	Sold10b5-1 plan	5,000	$27.80	139K	2.4%	Form 4
Jul 17, 2025	Cedric Francois Chief Executive Officer	Sold10b5-1 plan	19,725	$20.21	399K	1.0%	Form 4

Feb 11No plan
Mark Jeffrey Delong
Chief Business & Strat Officer · sold 368 at $22.15
8K
0.3% of stake
Jan 22No plan
Caroline Baumal
Chief Medical Officer · sold 2,797 at $21.77
61K
3.1% of stake
Jan 22No plan
James George Chopas
VP/Chief Accounting Officer · sold 2,064 at $21.77
45K
4.0% of stake
Jan 22No plan
Mark Jeffrey Delong
Chief Business & Strat Officer · sold 3,371 at $21.77
73K
4.1% of stake
Jan 22No plan
Pascal Deschatelets
Chief Scientific Officer · sold 5,928 at $21.77
129K
0.5% of stake
Jan 22No plan
Cedric Francois
Chief Executive Officer · sold 27,192 at $21.77
592K
1.7% of stake
Jan 22No plan
Nur Nicholson
Chief Technical Officer · sold 7,725 at $21.77
168K
9.8% of stake
Jan 22No plan
Timothy Eugene Sullivan
Chief Financial Officer · sold 10,287 at $21.77
224K
6.3% of stake
Jan 22No plan
David O. Watson
General Counsel · sold 7,832 at $21.77
171K
5.0% of stake
Jan 20No plan
Caroline Baumal
Chief Medical Officer · sold 1,882 at $19.79
37K
2.1% of stake
Jan 20No plan
James George Chopas
VP/Chief Accounting Officer · sold 726 at $19.79
14K
1.4% of stake
Jan 20No plan
Mark Jeffrey Delong
Chief Business & Strat Officer · sold 1,334 at $19.79
26K
1.6% of stake
Jan 20No plan
Pascal Deschatelets
Chief Scientific Officer · sold 909 at $19.79
18K
<0.1% of stake
Jan 20No plan
Cedric Francois
Chief Executive Officer · sold 8,182 at $19.79
162K
0.5% of stake
Jan 20No plan
Nur Nicholson
Chief Technical Officer · sold 2,203 at $19.79
44K
2.7% of stake
Jan 20No plan
Timothy Eugene Sullivan
Chief Financial Officer · sold 2,892 at $19.79
57K
1.7% of stake
Jan 20No plan
David O. Watson
General Counsel · sold 2,475 at $19.79
49K
1.6% of stake
Jan 13No plan
James George Chopas
VP/Chief Accounting Officer · sold 873 at $22.19
19K
1.6% of stake
Jan 13No plan
Mark Jeffrey Delong
Chief Business & Strat Officer · sold 1,780 at $22.19
39K
2.1% of stake
Jan 13No plan
Pascal Deschatelets
Chief Scientific Officer · sold 2,277 at $22.19
51K
0.2% of stake
Jan 13No plan
Cedric Francois
Chief Executive Officer · sold 10,186 at $22.19
226K
0.6% of stake
Jan 13No plan
Nur Nicholson
Chief Technical Officer · sold 2,618 at $22.19
58K
3.1% of stake
Jan 13No plan
Timothy Eugene Sullivan
Chief Financial Officer · sold 3,856 at $22.19
86K
2.3% of stake
Jan 13No plan
David O. Watson
General Counsel · sold 5,780 at $22.19
128K
3.5% of stake
Jan 5No plan
Caroline Baumal
Chief Medical Officer · sold 3,020 at $25.53
77K
3.2% of stake
Dec 16, 202510b5-1 plan
David O. Watson
General Counsel · sold 5,000 at $24.49
122K
3.0% of stake
Nov 17, 202510b5-1 plan
David O. Watson
General Counsel · sold 5,000 at $20.06
100K
2.9% of stake
Oct 21, 202510b5-1 plan
Timothy Eugene Sullivan
Chief Financial Officer · sold 10,000 at $28.03
280K
5.5% of stake
Oct 16, 202510b5-1 plan
David O. Watson
General Counsel · sold 5,000 at $25.22
126K
2.8% of stake
Oct 10, 202510b5-1 plan
A. Sinclair Dunlop
Director · sold 31,092 at $23.72
738K
16% of stake
Sep 30, 202510b5-1 plan
A. Sinclair Dunlop
Director · sold 31,092 at $22.58
702K
14% of stake
Sep 19, 202510b5-1 plan
A. Sinclair Dunlop
Director · sold 31,092 at $22.95
714K
12% of stake
Sep 16, 202510b5-1 plan
David O. Watson
General Counsel · sold 5,000 at $24.34
122K
2.7% of stake
Sep 15, 2025No plan
James George Chopas
VP/Chief Accounting Officer · sold 189 at $24.19
5K
0.4% of stake
Sep 10, 2025No plan
David O. Watson
General Counsel · sold 20,000 at $26.17
523K
9.8% of stake
Sep 8, 202510b5-1 plan
Timothy Eugene Sullivan
Chief Financial Officer · sold 42,729 at avg $27.85
$1.19M
20% of stake
Sep 2, 2025No plan
James George Chopas
VP/Chief Accounting Officer · sold 548 at $28.08
15K
1.0% of stake
Aug 27, 2025 – Aug 28, 2025No plan
Cedric Francois
Chief Executive Officer · sold 225,000 at avg $28.23
$6.35M
12% of stake
Aug 18, 202510b5-1 plan
David O. Watson
General Counsel · sold 5,000 at $27.80
139K
2.4% of stake
Jul 17, 202510b5-1 plan
Cedric Francois
Chief Executive Officer · sold 19,725 at $20.21
399K
1.0% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch APLS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with APLS

CompareIntrinsic value

ACADAcadia Pharmaceuticals Inc.

$21.49+4.47%74

PBHPrestige Consumer Healthcare Inc.

$53.28+7.55%48

MDGLMadrigal Pharmaceuticals, Inc.

$400.67+1.10%10

IONSIonis Pharmaceuticals, Inc.

$40.15-0.67%39

ANIPAni Pharmaceuticals Inc.

$72.89+0.84%85

INDVIndivior Pharmaceuticals, Inc.

$36.28+2.57%80

HRMYHarmony Biosciences Holdings, Inc.

$34.42-7.04%82

PTCTPTC Therapeutics, Inc.

$68.97+1.25%65

Held by ETFs

APLS is in 1 US ETF. The largest of them, with APLS's weight in each:

Avantis U.S. Quality ETFAVUQ0.00%of the fund

Spot a number that looks wrong? Check it in APLS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing APLS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.